An immunocapture-LC-MS-based assay for serum SPINK1 allows simultaneous quantification and detection of SPINK1 variants by Ravela, Suvi et al.
RESEARCH PAPER
An immunocapture-LC-MS-based assay for serum SPINK1 allows
simultaneous quantification and detection of SPINK1 variants
Suvi Ravela1,2 & Leena Valmu1,2 & Mykola Domanskyy1 & Hannu Koistinen1 & Leena Kylänpää3 & Outi Lindström3 &
Jakob Stenman4,5 & Esa Hämäläinen6 & Ulf-Håkan Stenman1,6 & Outi Itkonen1,6
Received: 16 October 2017 /Revised: 27 November 2017 /Accepted: 1 December 2017 /Published online: 9 January 2018
# Springer-Verlag GmbH Germany, part of Springer Nature 2018
Abstract
Pancreatic secretory trypsin inhibitor Kazal type 1 (SPINK1) is a 6420 Da peptide produced by the pancreas, but also by several
other tissues and many tumors. Some mutations of the SPINK1 gene, like the one causing amino acid change N34S, have been
shown to confer susceptibility to recurrent or chronic pancreatitis. Detection of such variants are therefore of clinical utility. So far
SPINK1 variants have been determined by DNA techniques. We have developed and validated an immunocapture-liquid
chromatography-mass spectrometric (IC-LC-MS) assay for the detection and quantification of serum SPINK1, N34S-
SPINK1, and P55S-SPINK1. We compared this method with a time-resolved immunofluorometric assay (TR-IFMA) for serum
samples and primer extension analysis of DNA samples. We used serum and DNA samples from patients with acute pancreatitis,
renal cell carcinoma, or benign urological conditions. With the help of a zygosity score calculated from the respective peak areas
using the formula wild-type (wt) SPINK1/(variant SPINK1 + wt SPINK1), we were able to correctly characterize the heterozy-
gotes and homozygotes from the samples with DNA information. The score was then used to characterize the apparent zygosity
of the samples with no DNA characterization. The IC-LC-MS method for SPINK1 was linear over the concentration range 0.5–
1000 μg/L. The limit of quantitation (LOQ) was 0.5 μg/L. The IC-LC-MS and the TR-IFMA assays showed good correlation.
The median zygosity score was 1.00 (95% CI 0.98–1.01, n = 11), 0.55 (95% CI 0.43–0.61, n = 14), and 0.05 (range 0.04–0.07,
n = 3) for individuals found to be wt, heterozygous, and homozygous, respectively, for the N34S-SPINK1 variant by DNA
analysis. When DNA samples are not available, this assay facilitates identification of the N34S- and P55S-SPINK1 variants also
in archival serum samples.
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Introduction
Serine peptidase inhibitor Kazal type 1 (SPINK1, also known
as pancreatic secretory trypsin inhibitor or PSTI and tumor-
associated trypsin inhibitor or TATI) is a 6240 Da peptide that
occurs at high concentrations in the pancreas and pancreatic
fluid, where it represents 0.1 to 0.8% of the total protein [1].
The main function of SPINK1 in the pancreas is to serve as the
first line of defense against premature activation of trypsino-
gens [1, 2]. SPINK1 is also expressed in several other normal
tissues, like the kidney [3], prostate [4], stomach, small intes-
tine, and colon [5]. In these, SPINK1 may function as a
growth factor, play a role in reproduction, or modulate apo-
ptosis and normal tissue differentiation and repair [6].
SPINK1 is also expressed in several cancers [6, 7].
Pancreatitis may be induced by inadvertent activation of
trypsinogens within the pancreas. It is characterized by
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inflammation and necrosis with swelling of pancreatic cells and
organelles, and loss of plasmamembrane integrity. This leads to
increased leakage of pancreatic enzymes and SPINK1 into cir-
culation. As a result, the concentrations of SPINK1 and tryp-
sinogens in plasma and urine may increase more than 100-fold
[8–10]. The sensitivities of serum SPINK1, amylase, and elas-
tase I in acute pancreatitis (AP) are similar [11], but because
SPINK1 also acts as an acute phase reactant [12], it has not
replaced the amylase assay in routine diagnostics of AP.
There are several known mutations in the SPINK1 gene which
also alter the amino acid sequence [13, 14]. The incidence of the
most common variants N34S (6214 Da, dbSNP:rs17107315)
and P55S (6231 Da, dbSNP:rs111966833) is 0.5–2.5% [15, 16]
and 0.5–3% [14–17], respectively. However, in chronic pancre-
atitis (CP) patients, the respective incidences are 9.1–28.6%
[16, 18–22] and 0.9–7.3% [15–17, 21]. In a Finnish population,
the N34S variant was found in 7.8% of AP patients, but there
was no difference in the frequency of the P55S variant between
the patients and controls [21]. The mechanism behind the asso-
ciation of the N34S variant with pancreatitis is not clear, be-
cause it is not known to alter expression, affinity for trypsin, or
trypsin inhibitory activity [23–25].
Previously described enzyme-linked immunosorbent assays
(ELISAs) [26–28], a time-resolved immunofluorometric assay
(TR-IFMA) [28, 29], and radioimmunoassays (RIAs) [7, 10]
for SPINK1 are based on antibodies, which are not known to
distinguish between different SPINK1 variants. We describe
here a novel assay based on immunocapture of SPINK1 from
serum and detection and simultaneous quantification of wild-
type (wt) SPINK1, N34S-, and P55S-SPINK1 variants by liq-
uid chromatography-mass spectrometry (IC-LC-MS).
Materials and methods
Samples
We used serum samples from patients with benign urological
conditions, with renal cell carcinoma, and suspicion of AP. In
addition, we analyzed serum samples from patients (n = 34)
with known SPINK1 variations confirmed by PCR amplifica-
tion and minisequencing [21]. AP was diagnosed as described
[30] at the Department of Surgery of Helsinki University
Central Hospital. Samples from AP patients were collected
during 2010–2012, from renal cell carcinoma (RCC) patients
and benign controls during 2004–2006 and AP patients with
known SPINK1 variations during 1998–2004, except for one
sample that was collected in 2008. Patient characteristics are
described in the Table 1. All samples were stored at − 20 °C
until analysis. Serum from an apparently healthy individual
was used as low level (11.2 μg/L) and, when spiked with
SPINK1 (63.4 μg/L), as high level quality assurance (QA)
sample. The QA samples were aliquoted and stored at −
80 °C. The study was approved by the ethical committee of
Helsinki University Central Hospital, Finland. Informed con-
sent was obtained from all individuals.
Production of calibrator and internal standard
Synthetic cDNAs encoding different SPINK1 forms and op-
timized for expression in Escherichia coli were from
GenScript. For the production of SPINK1 calibrator, we used
a cDNA encoding wt SPINK1 (Uniprot: P00995) and for an
internal standard a cDNA encoding SPINK1 with an S25T-
mutation (Fig. 1). Both cDNAs lacked the part encoding sig-
nal peptide (amino acids 1–23). The SUMOstar Expression
System (LifeSensors) was used for expression and purifica-
tion of both wt and S24T-mutated SPINK1 peptides in house.
Synthetic cDNA sequences were cloned into pE-
SUMOstar(Kn) vector and expressed in E. coli as fusion pro-
teins with an N-terminal SUMO protein carrying a His-tag at
the N-terminus. For peptide expression, E. coli BL21 (DE3)
cells (Novagen) were induced overnight with 0.5 mM
isopropylthio-β-galactoside (Calbiochem) after the optical
density reading at 600 nm of cell suspension reached 0.6.
The synthesized His-tagged peptides were purified using Ni-
NTA agarose (QIAGEN) and SUMO protein was released
from SPINK1 polypeptides by digestion with recombinant
His-tag containing SUMOstar protease. The protease and
SUMO protein were removed by incubation with Ni-NTA
agarose. Finally, SPINK1 was purified by immunoaffinity
chromatography and reversed-phase HPLC as previously de-
scribed [31]. The concentrations of wt SPINK1 and S25T-
SPINK1 were measured by the TR-IFMA for SPINK1 (see
below) and absorbance at 280 nm. Typical yields were ~1 mg
SPINK1 per liter of bacterial culture. The SPINK1 fractions
were stored at − 20 °C. A SPINK1 stock solution (73.3 mg/L)
was prepared by diluting purified wt SPINK1 with 50 mM
Tris-HCl, pH 7.5, and 150 mM NaCl (Tris-buffered saline,
TBS) containing 50 g/L bovine serum albumin (BSA, essen-
tially fatty acid and globulin free ≤ 99%, Sigma Aldrich), and
stored at +4 °C. Calibrators (0.5–1000 μg/L) were diluted
freshly from the stock solution with TBS containing 10 mg/
L BSA. To prepare the internal standard (IS) stock solution
(7.8 mg/L), purified S24T-SPINK1 was diluted with TBS
containing 50 g/L BSA and stored at + 4 °C. IS working so-
lution (150 μg/L) was diluted freshly from the stock solution
with TBS containing 10 mg/L BSA.
Immunocapture of SPINK1
Antibody (MAb 6E8) recognizing SPINK1 [28] was conju-
gated to magnetic Protein G Mag Sepharose (called Bbeads^)
using the crosslinking protocol provided by the manufacturer
(GE Healthcare). With this protocol, the antibody is covalent-
ly bound to the beads and it is not eluted with the antigen.
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Magnetic beads were coupled in batches (500μL of slurry at a
time, 1 mg MAb/100 μL bead slurry) and the coupled beads
were stored at + 4 °C.
To 100 μL of serum, QA samples and calibrators 20 μL of
IS (150 μg/L) was added. The calibrators were forwarded for
LC-MS analysis without capturing. SPINK1 in QA and serum
samples was captured using 20 μL of magnetic anti-SPINK1
bead slurry, i.e., 4 μL of beads. The beads were first washed
twice with TBS. Then, 100 μL of sample with IS was added to
the beads and incubated for 15 min with gentle shaking at
room temperature (Vortex-Genie 2 with a multiple sample
head, Scientific Industries). The beads were washed twice
with 2 M urea in TBS and once with TBS. Bound SPINK1
was eluted from the beads by adding 50 μL of 0.1% TFA and
incubating for 20 min with shaking. The supernatant was re-
moved and the elution was repeated. The supernatants were
combined and the eluted sample was centrifuged for 1 min at
1100 g to remove possible residual magnetic particles.
LC-MS
The instrumentation consisted of an Agilent 1200 liquid
chromatography (Agilent Technologies) and a 4000
QTRAP mass spectrometer (AB Sciex) equipped with a
Turbo-V electrospray ion source. We used a Polaris C18-
A column (3 μm particle size, 50 × 2 mm) with a Polaris
C18-A guard column (Agilent Technologies). Elution
buffers were 0.1% formic acid (FA) in water (A) and
0.1% FA in methanol (B). After injection of the sample
(20 μL), the proportion of buffer B was ramped from 20
to 100% in 3 min and maintained at 100% for further
3 min. The proportion of B was then reduced to 20% in
0.5 min and the column was equilibrated for further
3.5 min. The flow rate was 300 μL/min. The ion source
spray voltage was 5500 V and temperature 500 °C. The
gas settings were curtain gas 55 psig, nebulizer gas 50
psig, heater gas 45 psig, and collision gas setting 10. For
detection and quantification, we used pseudo-MRM with
the following transitions (m/z) with 250 ms dwell time:
1041.4/1041.4 (SPINK1, z = 6, for quantification),
1249.4/1249.4 (SPINK1, z = 5, for confirmation), and
1043.5/1043.5 (IS, z = 6), and with dwell time 100 ms:
1036.7/1036.7 (N34S-SPINK1, z = 6) and 1039.5/1039.5
(P55S-SPINK1, z = 6).
Analytical validation of the assay
The limit of detection (LOD) was based on a signal-to-noise
ratio (S/N) of 3 (n = 10). Linearity was determined by prepar-
ing eight calibrators with concentrations of 0.5–1000 μg/L in
Table 1 Patient data. Pancreatic amylase, amylase, and C reactive protein (CRP) were analyzed with the modular clinical chemistry analyzer (Hitachi
Ltd.) using reagent kits from Roche Diagnostics BmbH
Patient group Suspected AP RCC Benign urological conditions Confirmed SPINK1 genotype
Men/Women, n 24/8 18/14 15/16 23/11
Median age, years (range) 51 (25–86) 62 (43–87) 55 (26–79) 52 (20–86)
Median CRP, mg/L (range) 137 (6–414) – – 24 (5–397)
Median pancreatic amylase, U/L (range) 342 (8–2746) – – –
Median amylase, U/L (range) 366 (12–3618) – – 616 (59–5642)
AP/other patients 29/3 – – 6/28a




Clear cell/papillary RCC, n – 22/14 – –
Hematuria/other, n – – 19/12b –
a Chronic pancreatitis 5; alcoholic pancreatitis 10; biliary pancreatitis 5; other 7; unknown 1
bNephrolithiasis 5; ureterolithiasis 3; pollacisuria 2; cystitis recidivans 1; prostate hyperplasia 1
A
B
Fig. 1 The protein sequence of
SPINK1. Protein sequence of
wild-type SPINK1 (a). The signal
sequence is in gray. N34 and P55
are underlined. The sequence of
mutated (S25T) SPINK1 used as
internal standard (b). The mutated
threonine is bolded
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TBS containing 10 mg/L BSA. Evaluation of the resulting
calibration curves was performed with 12 separately prepared
dilutions. The stability of calibrator solutions was studied by
preparing six calibrator solutions (1–500 μg/L), which were
aliquotted and they were kept either at − 20 °C or at + 4 °C for
1 week to 3months. The stability was estimated by calculating
the coefficient of variation (CV%) of relative peak areas (cal-
ibrator peak area / IS peak area). The calibration curves were
derived using 1/x2 weighted linear least-squares regression by
the quantitation option of the Analyst 1.5 software (AB
Sciex). The accuracy (mean relative error, RE%) and the pre-
cision (CV%) were calculated. The limit of quantitation
(LOQ) and linear range were defined as the lowest concentra-
tion and range, respectively, which could be measured with an
inaccuracy and imprecision < 20%. Intra- and inter-assay var-
iation were calculated from 14 replicates in one and 15 con-
secutive assays, respectively. Recovery of added SPINK1 was
calculated from three samples supplemented with 0 μg/L,
20 μg/L, or 100 μg/mL of recombinant SPINK1. The matrix
effect was calculated from three immunopurified samples sup-
plemented with 0, 10, or 300 μg/L of purified SPINK1 and
25 μg/L of IS, respectively. To avoid carry-over, we recom-
mend sampler needle and injector valve washing procedures.
The effect of potential interfering substances is described in
the results.
Time-resolved immunofluometric assay
The time-resolved immunofluorometric assay (TR-IFMA) for
SPINK1 was performed as previously described [28, 29].
Briefly, MAbs F62-6E8 and F62-11B3 were used as capture
and tracer antibodies, respectively. F62-11B3 was labeled with
europium (Eu) using isothiocyanatophenyldiethylenetriamine-
N1,N2,N3,N4-tetraacetate chelated with Eu(III) [32].
Microtitration wells were coated with F62-6E8 and 25 μL of
calibrators (from 0.5 to 90 μg/L) and samples together with
200 μL DELFIA® assay buffer (PerkinElmer) were added to
the wells and incubated at room temperature for 1 h. All incu-
bations were performed under constant shaking (DELFIA®
Plateshake, PerkinElmer). The wells were washed twice with
DELFIA® Wash solution (PerkinElmer) and 50 ng of Eu-
labeled tracer in 200 μL of assay buffer was added per well
and incubated for 30 min. After four washes, DELFIA®
Enhancement solution (PerkinElmer) was added with a
Delfia® plate dispenser (PerkinElmer) and the fluorescence
measured for 1 s per well using a Victor2 1420 Multilabel
HTS Counter (PerkinElmer).
Statistical methods
The coefficient of variation, Student’s t test, and Bland-
Altman plot were calculated with Analyse-it for
Microsoft® Excel 2003 (version 2.04, http://www.
analyse-it.com/). Other analyses were performed with R
(version 2.13.0) package Bpsych^ (version 1.2.8, http://
personality-project.org/r/), Bepicalc^ (version 2.15.1.0,
http://CRAN.R-project.org/), and with BMethComp^
(version 1.22, http://bendixcarstensen.com/MethComp/).
Results
Validation of the LC-MS assay for SPINK1
SPINK1 and the IS eluted at a retention time of 3.3 min
(Fig. 2). The LC-MS assay for SPINK1 was linear over
the concentration range of 0.5–1000 μg/L, but as work-
ing calibrators we routinely used 1–500 μg/L (Fig. 3).
Calibrators at concentrations of 2–500 and 5–500 μg/L
were stable for 2 months at − 20 °C and at + 4 °C, re-
spectively. The LOD was 0.15 μg/L and the LOQ was
0.5 μg/L. The intra-assay CVs were 6.4 and 4.2% and
the inter-assay CVs 17.7 and 16.4% at concentrations of
11 and 75 μg/L, respectively. The recovery of added
SPINK1 (20 and 100 μg/L) in serum samples containing
11.2, 50.3, and 273 μg/L endogenous SPINK1 was 87–
100%. When spiked into immunopurified serum, we ob-
served ionization suppression to 88 and 58% for 10 and
300 μg/L of SPINK1, respectively, and to 77% for the IS
(25 μg/L). As calculated from the peak areas of samples
spiked with SPINK1 (10 and 300 μg/L) or IS (25 μg/L)
either pre- or post-immunocapture, the recovery of the
immunopurification was 91 and 129% for SPINK1, re-
spectively and 94% for the IS. When measured by TR-
IFMA, the recovery for SPINK1 was 100%.
Detection of SPINK1 variants by LC-MS
The m/z difference of the sextuply charged ions of wt
SPINK1 (6240 Da) , N34S- (6214 Da) , P55S-
(6231 Da), and S25T-SPINK1 (6255 Da) used as IS al-
lows mass spectrometric analysis of each SPINK1 form
separately. The mean SPINK1 concentration in serum
samples from AP patients with confirmed N34S-
SPINK1 (n = 17) or P55S-SPINK1 (n = 6) variant was
143 μg/L (95% CI 49.8–164 μg/L) as measured by the
TR-IFMA. The mean wt SPINK1 concentration by LC-
MS assay was 67.2 μg/L (22.1–81.7 μg/L) and the mean
total SPINK1 concentration, i.e., the sum of wt SPINK1,
and N34S-SPINK1 or P55S-SPINK1 was 107 μg/L
(49.8–163.4 μg/L).
To estimate the ability of our LC-MS assay to distin-
guish between homozygous and heterozygous SPINK1
variation carriers, we compared the peak areas of the
samples from individuals with confirmed SPINK1 geno-
type [21]. The peak area of wt SPINK1 and N34S-
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SPINK1 is approximately equal in samples from hetero-
zygous subjects (Fig. 2c). However, in the chromatogram
of a homozygous N34S-SPINK1 carrier’s sample (Fig.
2d), only a minor if any signal of wt SPINK1 is seen.
In order to numerically represent the apparent genotype
based on LC-MS, we calculated a zygosity score as the
ratio of wt SPINK1 to total SPINK1, i.e., wt SPINK1/
(mutated SPINK1 + wt SPINK1), from the respective
peak areas of the samples. In samples from confirmed
homozygous N34S-SPINK1 carriers (n = 3), confirmed
heterozygous N34S-SPINK1 carriers (n = 13), and control

























































Fig. 2 LC-MS chromatograms. LC-MS chromatograms of a 5 μg/L re-
combinant SPINK1 calibrator (a) and samples from confirmed wild-type
(b), heterozygous N34S- (c), homozygous N34S- (d), and heterozygous
P55S-SPINK1 (e) individuals. The lines from black to the lightest gray
represent wt SPINK1 m/z 1041.4 (z = 6) and m/z 1249.4 (z = 5), N34S-
SPINK1 (m/z 1036.7, z = 6), P55S-SPINK1 (m/z 1039.5, z = 6), and IS
(m/z 1043.5, z = 6), respectively. Y-axis shows the peak height (cps) and x-
axis the chromatographic elution time (min)





















Fig. 3 Calibration curve of the
IC-LC-MS analysis SPINK1 cal-
ibration curve showing the linear
range of the assay
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zygosity score was 0.05 (range 0.04–0.07), 0.55 (95% CI
0.43–0.61), and 1.00 (95% CI 0.98–1.01), respectively
(Fig. 4). The result of one heterozygous N34S carrier
(1.03) was excluded as an outlier after repeated DNA
and LC-MS analyses. Patients with confirmed P55S-
SPINK1 (Fig. 2e) variant were all heterozygous (n = 6)
with a median zygosity score of 0.56 (range 0.53–0.76).
Variability of the zygosity score was studied with repeat-
ed assays (n = 5–7) of each different type of patients. The
coefficient of variation in the zygosity score was the
lowest (0.8–5.0%) for the wild-type samples (range
0.88–1.02), 4.9–21.5% for heterozygous N34S or P55S
samples (range 0.31–0.76), and the highest (46.1–73.5%)
for homozygous N34S samples (range 0.03–0.29).
Therefore, we suggest that a zygosity score > 0.8, 0.3–0.8,
and < 0.3 indicates a wt, heterozygous, and homozygous ge-
notype, respectively.
The effect of interfering substances
To study the effects of potential interfering factors to our
assay, we selected among our patient samples (stripped
of identifiers) those with elevated rheumatoid factor (449
and 986 IU/mL), lipemia (L-index 76 and 347 by Roche
Modular clinical chemistry analyzer), monoclonal
gammopathy with IgG6 (56 g/L), IgM1 (21 and 29 g/
L), IgA2 (45 g/L) (by capillary electrophoresis and aga-
rose gel electrophoresis followed by immunofixation),
and one sample with interference in our THS assay
(21.5 mU/L with Abbott Architect immunoanalyzer).
After this sample was treated with heterophilic blocking
tube (HBT from Scantibodies Laboratory, Inc., Santee,
CA) and reanalyzed, the TSH result was 1.5 mU/L.
Therefore, the interfering factor was likely to be
heterophilic antibodies.
Serum samples from pancreatitis patients with confirmed
wild-type or heterozygous N34S genotype (by DNA analysis)
were diluted 1:2 with interfering serum samples. Interfering
substances were found to cause decreased SPINK1 results
(mean 74%, range 54–115% of expected concentration,
Table 2). On the other hand, the interference was sample de-
pendent, i.e., the change in expected concentration of two
different patient samples by one interfering sample varied be-
tween 54–115% (rheumatoid factor) and 55–101% (monoclo-
nal IgG6).
Comparison of TR-IFMA and LC-MS assay for SPINK1
In addition to the patients with previously identified
SPINK1 variants, we analyzed 95 serum samples from
patients with RCC, benign urological conditions, and
suspected for AP. In AP patients, the mean serum concen-
tration of SPINK1 was 243 μg/L (95% CI 178–307 μg/L)
by the TR-IFMA and 274 μg/L (95% CI 181–368 μg/L)
by the LC-MS assay. In RCC patients, the concentrations
were 32.2 μg/L (95% CI 18.8–45.6 μg/L) and 45.4 μg/L
(95% CI 16.9–73.9 μg/L) and in benign controls
11.3 μg/L (95% CI 9.7–12.9 μg/L) and 12.6 μg/L (95%
CI 10.7–14.5 μg/L), respectively. There were no signifi-
cant differences between SPINK1 concentrations as mea-
sured by the TR-IFMA and the LC-MS assay except in
samples from benign controls (p < 0.05) (Fig. 5). The re-
sults by TR-IFMA (x) and LC-MS (y) correlated accord-
ing to an equation y = 1.17x − 13.6 (Deming regression,
Sy|x = 0.498, R2 = 0.94, n = 95).
We observed by IC-LC-MS an apparent N34S-
SPINK1 variant in 4 of 32 (12.5%) samples from
suspected AP and in 1 of 32 (3.1%) samples from
RCC patients. The genotype of these patients has not
been confirmed by DNA analysis. The zygosity scores
were 0.58, 0.55, 0.35, 0.54, and 0.05. This suggests that
one of the patients is a homozygous and four are hetero-
zygous N34S-SPINK1 carriers. We did not see a P55S-
SPINK1 variant in patient samples that were not previ-
ously genotyped.
Discussion
We have developed an immunocapture-LC-MS assay for
simultaneous detection and quantification of serum wt
SPINK1, and N34S-SPINK1 and P55S-SPINK1 variants.
The assay employs a SPINK1 antibody coupled to mag-























































wt SPINK1 he N34S-SPINK1 ho N34S-SPINK1
Fig. 4 Calculated zygosity scores according to confirmed genotype.
Calculated zygosity scores (wt SPINK1/total SPINK1 peak areas) are
plotted separately for samples from confirmed wt individuals (wt
SPINK1), heterozygous N34S-SPINK1 carriers (he N34S-SPINK1),
and homozygous N34S-SPINK1 carriers (ho N34S-SPINK1). The result
(1.03) of one heterozygous individual is deleted as an outlier
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recombinant S25T-SPINK1 internal standard. The assay
range is wide (0.5–1000 μg/L). The sensit ivity
(0.5 μg/L) is comparable to that of a previously de-
scribed TR-IFMA (0.13 μg/L) and ELISA (0.8 μg/L)
for SPINK1 [28] and clearly better than that of a former
commercial radioimmunoassay (7 μg/L). The high sensi-
tivity and the wide assay range of our new assay are
advantageous both in clinical and research settings.
The present assay is based on pseudo-MRM employing
low collision energy to reduce possible isobaric interferences.
Table 2 The effect of interfering
substances to SPINK1
concentration as measured by
immunocapture-LC-MS. Serum
samples were diluted 1:2 with
samples containing the denoted
amount of interfering substance.
Theoretical SPINK1
concentration was calculated as
the mean of SPINK1
concentration measured in the
interfering sample and the patient
sample
Measured SPINK1 (μg/L) Theoretical
concentration
Interfering factor Interf. sample Patient sample Interf:Patient 1:1 μg/L %
Rheumatoid factor 449 IU/mL 90 518 164 304 54
100 45 83 72 115
Rheumatoid factor 986 IU/mL 27 518 156 272 57
21 45 23 33 70
Lipemic index 76 80 518 224 299 75
56 45 36 50 71
Lipemic index 347 36 518 197 277 71
26 45 20 35 57
Monoclonal IgG6 56 g/L 53 518 158 285 55
46 45 46 46 101
Monoclonal IgM1 21 g/L 137 518 230 328 70
Monoclonal IgM1 29 g/L 56 45 33 51 64
Monoclonal IgA2 45 g/L 70 518 202 294 69
77 45 68 61 111
Heterophilic interference 14 256 93 135 69




















Fig. 5 Comparison of TR-IFMA and LC-MS results. Serum samples
from patients suspected for AP (n = 32), with RCC (n = 32) and with
benign urological conditions (n = 31) were measured by IC-LC-MS and
TR-IFMA. In the Bland-Altman plot, the absolute difference between the
two methods is plotted against their mean. Gray line shows identity and
dotted line 95% limits of acceptance. The insert shows comparison of
SPINK1 concentrations 4.7–96.6 μg/L with a log scale x-axis. One sam-
ple from anAP patient with a SPINK1 concentration 713μg/L by the TR-
IFMA and 1440 μg/L by the IC-LC-MS assay is not shown. Samples
with newly found apparent heterozygous N34S-SPINK1 variants are
circled
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Especially at low concentrations, the mean SPINK1 concen-
trations were slightly higher by our IC-LC-MS than immuno-
assay suggesting a minor bias. In general, multiple reaction
monitoring (MRM)-based assays are more specific and sensi-
tive. However, an MRM assay of 6240 Da SPINK1 was not
possible without an extra step of enzymatic digestion. We
found that common known interfering factors may decrease
the measured SPINK1 concentration. Thus, it should be kept
in mind that immunocapture in non-diluted serum may be
prone to interference, which is also the case with conventional
immunoassays. The newly developed assay for total serum
SPINK1 and the previously described TR-IFMA for
SPINK1 [28] show relatively good correlation. Therefore,
we consider the present straightforward pseudo-MRM assay
suitable for quantification of SPINK1 and especially for de-
tection of SPINK1 variants.
In LC-MS analysis, an ideal IS corrects for the recovery
during sample preparation and chromatography and for the
matrix effects during ionization. The most common practice
is to employ a stable isotopically labeled (SIL) IS especially
for small molecules. The use of an analog peptide is an alter-
native for SIL in peptide assays. A non-isotopic mutated IS
peptide, in which leucine was replaced with alanine, has been
compared to a SIL peptide for analysis of NAD(P)H:quinone
oxidoreductase 1 (NQO1) [33]. NQO1 was quantified in ex-
tracts of cells and tumor tissues and there was no significant
differences in the results between these two ISs. We used
mutated recombinant S25T-SPINK1 as an internal standard.
Such a mutation has not been described in endogenous
SPINK1. Replacement of serine with threonine in SPINK1
was not expected to alter the chemical properties of the pep-
tide. Indeed, the chromatographic and ionization properties of
wt SPINK1 and S25T-SPINK1 were found to be similar. The
acceptable correlation of our IC-LC-MS assay with TR-IFMA
for SPINK1 suggests that S25T-SPINK1 is suitable for use as
an IS.
Thus far, SPINK1 has been quantified by immunoassays
often with high sensitivity. The selectivity depends on the
antibodies employed, but immunoassays may lack specificity
[34, 35]. A unique property of MS-based methods compared
to immunoassays is the ability to detect different isoforms [36]
and posttranslational modifications [31, 37]. For example,
four different forms of Ras protein have been detected and
quantified by LC-MS in tumor tissue, premalignant pancreatic
cyst fluids, and cell lines [36]. However, only the relative
abundance of these isoforms, not the absolute quantity, could
be determined. Mass spectrometric detection of wt SPINK1,
N34S-, and P55S-SPINK1 has been demonstrated earlier [31],
but the method was not quantitative. We show that by using
S25T-mutated SPINK1 as an IS, it is possible to quantify wt
SPINK1, N34S-, and P55S-SPINK1 in serum samples. As
expected, the concentration of wt SPINK1 by LC-MS was
much lower than total SPINK1 concentration by TR-IFMA
in serum samples from heterozygotes, but the total SPINK1
concentration (wt SPINK1 + mutated SPINK1) by LC-MS
was in line with TR-IFMA results. This finding supports that
the quantitative performances of S25T-, N34S-, P55S-
SPINK1, and wt SPINK1 in our pseudo-MRM assay are
similar.
We found that the IC-LC-MS analysis can be used to de-
termine the apparent zygosity of the variants N34S- or P55S-
SPINK1 with the help of zygosity score. The score can be
calculated based on the ratio of the peak areas of wt- and total
SPINK1. By this means, the zygosity score of all confirmed
wt subjects (n = 11), homozygous N34S carriers (n = 3), and
13 of 14 heterozygous subjects were in accordance with the
DNA data. According to the zygosity score, one subject ap-
peared to have repeatedly a wt phenotype (score 1.03) despite
the heterozygous genotype. There are several possible expla-
nations for this discrepancy. First, it is possible that both al-
leles are not always expressed equally at the protein level. The
proportion of N34S-SPINK1 has been found to be higher than
that of wt SPINK1 in urine (n = 12) and sera (n = 2) of hetero-
zygous pancreatitis patients as shown earlier in a limited study
[31]. On the other hand, this is not supported by our present
data. Secondly, it is possible that yet another mutation results
in the same m/z as that for wt SPINK1. Thirdly, a human
mistake in sample tagging is possible. The number of patients
(n = 34) with confirmed SPINK1 variants in our study is lim-
ited. Therefore, further studies comparing the zygosity score
and DNA analysis are warranted. The current results are, how-
ever, promising, and may provide a new DNA-free detection
of known variants of SPINK1.
The presence of N34S-SPINK1 variant, but not the zygos-
ity, has been shown to associate with increased risk of devel-
oping CP after a sentinel AP incident [16, 21, 38–40].
However, the variant does not increase the risk of the first
incident. The occurrence of the variant in Finnish general
population is 2.5% [16, 21] and in patients with AP and CP,
it is 7.8% [21] and 12% [16], respectively. Thus, the occur-
rence of N34S-SPINK1 in samples from AP (13%) and be-
nign urological disease (1.6%) patients whose genotype has
not been confirmed by DNA analysis is in line with earlier
reports. Sentinel AP patients carrying the N34S-SPINK1 var-
iant have been shown to be about 19 times more prone to
develop recurrent attacks [20]. Therefore, identification of
N34S-SPINK1 carriers with an initial attack of AP could be
used to prevent recurrent attacks or progression of AP to CP.
Furthermore, our new assay enables identification of SPINK1
variants also in archival samples when DNA is not available.
In conclusion, we have developed an immunocapture-LC-
MS assay for serum SPINK1 and compared it with an immu-
noassay. The recombinant mutated SPINK1 used as an inter-
nal standard offers a cost-effective alternative to stable
isotope-labeled peptides. In addition to wt SPINK1, our new
assay facilitates detection and quantification of N34S- and
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P55S-SPINK1 variants known to associate with pancreatitis.
Moreover, by calculating a wt-to-total SPINK1 ratio, it is pos-
sible to determine the apparent zygosity of the variant without
DNA analysis. Therefore, this assay could be used for variant
screening and may help identifying patients with increased
risk for CP due to SPINK1 variants.
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